Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IRulya Therapeutics Inc. (IRLA)

IRulya Therapeutics names Brigette Roberts CEO as Quince completes Orphai merger and rename

Neutral Impact 4 of 5 leadership Written later

Quince Therapeutics renamed itself IRulya Therapeutics effective October 9, 2026, following its merger with privately held Orphai Therapeutics. Brigette Roberts, M.D., was appointed Chief Executive Officer effective October 8, 2026, succeeding Dirk Thye, M.D., who resigned as CEO, Chief Medical Officer and director, and John Militello, CPA, and Keith Fandrick, Ph.D., were named Chief Financial Officer and Chief Operating Officer. The company's common stock is expected to begin trading on Nasdaq under the symbol IRLA on October 12, 2026.

Key points

  • Brigette Roberts, M.D., named CEO effective October 8, 2026, with an annual base salary of $600,000 and a target bonus of 50% of base salary
  • John Militello, CPA, named CFO with a $440,000 base salary; a restricted stock unit award for 80,000 shares is subject to Board approval
  • Keith Fandrick, Ph.D., named COO with a $450,000 base salary; Brendan Hannah resigned as COO, Chief Business Officer and Chief Compliance Officer
  • Cash balance of $116 million as of June 30, 2026, expected to fund operations through the end of 2028; common stock expected to be about 10,841,470 shares after Series C conversion

The filing

CompanyIRulya Therapeutics Inc. (IRLA)
Form8-K, current report
Filed with the SECOct 9, 2026, 7:59 AM ET
Accession number0001193125-26-418538

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.